Department of Cardiology, Kishiwada City Hospital, Kishiwada-shi, Osaka 596-8501, Japan.
J Cardiol. 2008 Jun;51(3):171-8. doi: 10.1016/j.jjcc.2008.02.003. Epub 2008 Apr 18.
Statins are widely administered to patients with acute myocardial infarction (AMI), but knowledge of the effects of early statin therapy on the long-term mortality of AMI patients after stent implantation is still limited, especially for beyond low-density lipoprotein cholesterol (LDL-C) lowering effects.
Our 378 consecutive AMI patients who were discharged alive from the hospital with successful stent implantation between 1997 and 2005 were included. We retrospectively evaluated the effects of statin therapy on major adverse cardiovascular events (MACE), including all-cause death, reinfarction, coronary artery bypass grafting, heart failure requiring rehospitalization, and target lesion revascularization.
Statins were given to 271 patients according to the physician to achieve a LDL-C level of less than 100mg/dL. The achieved LDL-C levels in the statin group were 100.7, 95.1, 96.7, and 102.8mg/dL at discharge, 6 months, 1 year, and 3 years, respectively, whereas those in the non-statin group were 103.2, 107.3, 102.8, and 103.0mg/dL. These levels were not significantly different between the groups during 3 years. Based on Kaplan-Meier estimates, statin therapy was associated with a reduction of long-term mortality (log-rank test P=0.007). Multivariate Cox regression analysis revealed that statin therapy (P=0.015, hazard ratio: 0.10; 95% confidence interval: 0.01-0.64) was a significant predictor of favorable prognosis. Multivariate analysis revealed that statin treatment had a beneficial effect against MACE over 3 years (P=0.008).
Early statin therapy was beneficial for long-term mortality of AMI patients treated with stenting.
他汀类药物广泛用于急性心肌梗死(AMI)患者,但早期他汀治疗对支架植入后 AMI 患者长期死亡率的影响仍知之甚少,特别是在降低低密度脂蛋白胆固醇(LDL-C)以外的效果方面。
我们纳入了 1997 年至 2005 年期间因成功支架植入而从医院出院的 378 例连续 AMI 患者。我们回顾性评估了他汀类药物治疗对主要不良心血管事件(MACE)的影响,包括全因死亡、再梗死、冠状动脉旁路移植术、需要再次住院的心衰以及靶病变血运重建。
根据医生的建议,271 例患者给予他汀类药物以达到 LDL-C 水平低于 100mg/dL。他汀组出院时、6 个月、1 年和 3 年的 LDL-C 水平分别为 100.7、95.1、96.7 和 102.8mg/dL,而非他汀组分别为 103.2、107.3、102.8 和 103.0mg/dL。在 3 年内,两组之间的这些水平没有显著差异。根据 Kaplan-Meier 估计,他汀治疗与长期死亡率降低相关(对数秩检验 P=0.007)。多变量 Cox 回归分析显示,他汀治疗(P=0.015,风险比:0.10;95%置信区间:0.01-0.64)是预后良好的显著预测因素。多变量分析显示,他汀治疗在 3 年内对 MACE 有有益的效果(P=0.008)。
早期他汀治疗对接受支架治疗的 AMI 患者的长期死亡率有益。